Hypoxia is linked to changes in blood brain barrier (BBB) permeability and loss of BBB integrity is characteristic of many pathological brain diseases including stroke. In particular astrocytes play a central role in brain homeostasis and BBB function. We investigated how hypoxia affects astrocyte survival and assessed whether VEGF release through Hif-1 induction plays a role in tolerance of these cells to insult. Thus primary astrocytes were subjected to normoxic (21% O 2 ), hypoxic (1% O 2 ) or near anoxic (<0.1% O 2 ) conditions in presence or absence of glucose. Cell death was significantly initiated after combined oxygen glucose deprivation and surprisingly, astrocyte proliferation increased concomitantly. Near anoxic, but not hypoxic, conditions stabilised HIF-1 protein and provoked DNA binding activity whereas oxygen and glucose deprivation accelerated HIF-1 accumulation.
INTRODUCTION
Cerebral ischemia disrupts the BBB thereby irreversibly damaging neurons and astrocytes (27, 30) and often causing lethal cerebrovascular diseases. The blood brain barrier (BBB) consists of highly specialised vessels with a specific architecture that maintains homeostasis of the brain environment. Astrocytes, the most abundant cells in the brain, contact the brain vasculature with their endfeet processes and this interaction is thought to induce endothelial tight junction formation and decrease permeability of the BBB (48). Astrocytes are known to be more resistant to oxidative stress than neurons (25) and play a neuroprotective role through their ability to take up potassium and glutamate and release mitogenic factors (43) . However in response to injury, astrocytes retract their end feet from vessels resulting in increased permeability, as well as proliferate giving rise to a glial scar (24, 33, 45) . Since both of these events can have significant detrimental effects on the brain understanding how these complex cells respond to insult is important to limit vascular leakage and subsequent brain damage.
Hypoxic/ischemic insults cause activation of adaptive mechanisms and alteration of gene expression within the injured areas to combat the progression of pathological events (1) . Accordingly, at the cellular level an oxygen sensing system is crucial to enable rapid adaptation to altered oxygen tensions. A well-characterised molecular pathway that mediates oxygen sensing occurs through the induction of the transcription factor HIF-1 (hypoxiainducible factor-1). HIF-1 consists of an oxygen-dependent subunit and a constitutively expressed subunit. Both subunits are basic-helix-loop-helix (bHLH) proteins of the PAS family and complex binding enhances the transcription of target genes involved in glycogenesis, erythropoiesis and angiogenesis (16, 46) . HIF-1 is mainly regulated at the protein level by O 2 . During normal O 2 supply HIF-1 is hydroxylated by oxygen dependent prolyl-4-hydroxylases, ubiquitinated and rapidly degraded by the proteosomal system (11, 41) . Hypoxia stabilises HIF-1 and promotes its translocation to the nucleus, accumulation and dimerisation with HIF-1 ultimately enhancing transcriptional activity of its target genes through binding to its hypoxia response element.
A major HIF-1 target gene known to have a cytoprotective role is the potent angiogenic molecule VEGF (vascular endothelial growth factor) (10, 13) . VEGF binds with high affinity to two receptor tyrosine kinases, flt-1 (VEGFR-1) and flk-1 (VEGFR-2), and activates downstream pathways (reviewed in (36) ) promoting angiogenesis during development, as well as (patho)physiological events such as pregnancy, wound healing, rheumatoid arthritis, cardiovascular disease and cancer (12, 34) . Notably, astrocytes secrete basal levels of VEGF under normal physiological conditions and hypoxia further induces both mRNA and protein levels (8, 23, 39) . Although application of endogenous VEGF also causes increased vascular permeability and proliferation of glial cells (24, 49) , the importance of endogenous VEGF production to survival of astrocytes has not been shown conclusively.
Since astrocytes play a crucial role in brain homeostasis, their response to hypoxic/ischemic insult deserves further investigation. The aim of the present study was to investigate and compare the astrocytic response to mild and severe hypoxic/ischemic insults. Specifically we examined the influence of oxygen-and glucose-deprivation on HIF-1 stabilisation and expression of VEGF in primary rat astrocytes. We show that astrocytes induce HIF-1 only during prolonged severe insult but that this induction is not fully responsible for VEGF production, indicating other mechanisms of control. Importantly, endogenous VEGF expression constitutes an important astrocyte mitogen and survival factor.
MATERIALS AND METHODS

Primary culture of astrocytes
Primary astrocytes were prepared from newborn Wistar rat pups as previously described (8) .
Briefly neonatal rats were anesthetised by hypothermia, decapitated and cerebral cortices removed. Meninges were removed and cortices minced and placed in ice cold buffer (Krebs solution 120mM NaCl, 3mM KCl, 1.2mM MgSO 4 , 1.2mM KH 2 PO 4 , 25mM NaHCO 3 , 11mM glucose and 0.6g/l BSA). Homogenised tissue was digested with 7.5mg trypsin for 15 min at 37°C and dissociated cells were cultured in DMEM containing 10% FBS, 150mg/l LGlutamine and 50mg/ml Gentamicin at 37°C. The culture medium was changed every 4-5 days. After 10 days cultures displayed uniform (> 96%) glial fibrillary acidic protein (GFAP) immunoreactivity. Astrocytes were passaged a maximum of 3 times and used at 80-90% confluency. In some experiments a potent and selective inhibitor of Flk-1 kinase, SU1498 (Calbiochem), was used at a concentration of 0.1 and 10µM to inhibit VEGF activity.
Hypoxic and glucose deprivation experiments
For all experiments, primary astrocytes were incubated under normoxic (21% O 2 ), hypoxic (1% O 2 ) or near anoxic (<0.1% O 2 ) conditions in a purpose built humidified glove-box incubator (In vivo 400, Ruskinn technologies, UK). Glucose deprivation experiments were carried out with glucose-free DMEM (Life technologies).
Western blot analysis
Cells were scraped into lysis buffer (0.27 M Sucrose, 2mM EDTA (pH 8.0), 0.1% NP-40, in 0.6M KCl, 150mM NaCl, 150mM HEPES (pH 7.5)) and centrifuged for 10 min at 16'000 rcf.
Cytoplasmic fractions were frozen and nuclear pellets resuspended in nuclear extraction buffer (20mM HEPES (pH 7.5), 400mM NaCl,1mM EDTA(pH8.0)) and left 15 min on ice.
Nuclear extracts were obtained after centrifugation (16'000 rcf) for 10 min and separated by denaturing SDS-PAGE. After transfer to nitrocellulose membranes were incubated in 4% milk in PBS for 1h at room temperature then were incubated overnight at 4°C with antibodies against HIF-1 IgY (6) (diluted 1:100 in PBS). Following washes, membranes were incubated with a secondary HRP-conjugated antibody for 1h at room temperature.
Membranes were exposed to X-ray film after luminescent detection (25µl of 90mM coumaric acid in DMSO, 50µl of 250mM luminol in DMSO in 10ml of 100mM Tris, pH 8.5). For loading controls blots were stripped and re-probed for the nuclear protein Sp-1. Results were quantified by densitometry using BioRad Quantity One software (BioRad laboratories AG, CH).
VEGF ELISA
Quantitation of VEGF was performed using a VEGF ELISA kit (R&D Systems GmbH, Germany) according to manufacturers instructions. Optical density was measured using a microplate reader (Multiskan RC; Thermo Labsystems, Finland) at 450nm with wavelength correction at 570nm.
EMSA (electrophoretic mobility shift assay)
EMSA was performed radioactively with nuclear extracts as previously described (22) .
Oligonucleotide probes derived from the EPO enhancer gene 5'-GCC CTA CGT GCT GTC TCA-3' (3'EPO enh) and 5'-TGA GAC AGC ACG TAG GGC-3' (5'EPO enh.rev) were synthesized by Microsynth (Balgach, Switzerland). End-labelling was performed with T4 PNK (Fermentas, LabForce AG, Nunningen, Switzerland) at 37°C for 1h. Anti-sense oligonucleotides were added in 2-fold molar excess and annealed at 95°C for 3min. Samples were loaded on a 4% non-denaturing gel and electrophoresis was performed at 200V in 1xTBE buffer at 4°C. After drying the gel was visualised using BioRad Molecular Imager FX.
In situ labelling of fragmented DNA TUNEL labelling was carried out according to the manufacturers instructions (Roche Biochemicals, Penzberg, Germany). Astrocytes grown on cover slips and subjected to different conditions were fixed for 30 min in 4% paraformaldehyde. Staining was carried out in a humidified atmosphere for 1 hour and nuclei were counterstained with DAPI for 3min.
Samples were analysed by fluorescence microscopy.
Proliferation Assays
AlamarBlue assay was used to quantitatively measure astrocyte proliferation. Experiments were performed according to the manufacturers instructions (AlamarBlue; Biosource, Camarillo, CA). In brief primary astrocytes were seeded on 96-well plates at a density of 2000 cells per well and incubated overnight. Four hours prior to measurement 20µl of AlamarBlue dye was added to each well and plates were incubated under normoxic, hypoxic or anoxic conditions with or without glucose as described above. Absorbance was measured with a plate reader (Multiskan RC; Thermo Labsystems, Finland) at 540nm subtracting the background absorbance at 630nm.
Thymidine incorporation assay was used as an alternative method to AlamarBlue. Cells were grown to 90% confluency on 24 well plates overnight. At time 0, individual plates were exposed to normoxia, hypoxia or near anoxic conditions in presence or absence of glucose after addition of 1Ci [3 H ]thymidine. After 6 hours the astrocytes were washed with ice cold PBS, typsinised and harvested onto glass fiber filters (Wallac, Hünenberg, Switzerland). The amount of incorporated radioactivity was counted using a Wallac counter.
In all proliferation assays individual experiments, including those with inhibitor application,were performed 5 times in quadruplicate and data was converted to fold change compared to normoxic cells grown in glucose containing media.
ATP measurements
ATP was measured with an ATP bioluminescent assay kit (Sigma chemical company, Buchs, Switzerland). Cells were lysed in buffer (105mM NaCl, 1% Triton X-100, 1% NP-40, 50mM
Tris) for 10 min before centrifugation (10 min at 16'000 rcf). The supernatant was mixed with TCA 5% (1:1 v/v) to block residual ATPase activity, centrifuged for 1 min at 16'000 rcf and neutralized with saturated Tris solution to pH 7.8. Sample was added to diluted ATP assay mix (1:1 ratio) and luminescence measured using Berthold luminometer (Detection systems GmbH, Pforzheim, Germany). Cellular ATP levels were determined from a standard curve and normalised to total protein concentrations.
Hif-1 siRNA experiments
RNA interference was performed using a pool of short interfering RNAs targeting rat Hif1
(as well as a non-targeting control siRNA) purchased from Dharmacon Research Inc (L-091718-00; ON-TARGET plus siRNA). 60% confluent rat astrocytes were transfected with 100nM siRNA using Oligofectamine (Invitrogen) according to manufacturer's instructions.
Briefly, cells were washed with PBS and astrocyte medium was replaced with DMEM without antibiotic then siRNA duplexes were added in Opti-MEM (Gibco). After 4 hours transfection the medium was resupplemented with serum and antibiotics. Cells were exposed to hypoxia and/or glucose deprivation for the times indicated and proteins were extracted for analysis 48h post transfection.
Statistical analyses
Graphics and statistical analyses were performed using Microsoft excel software. All results are expressed as fold change over normoxic values. Statistical significance (P< 0.05%) was calculated using student T-test.
RESULTS
Increased severity of insult stimulates astrocytic proliferation
Since injury induces increased proliferation of glial cells and formation of a glial scar in vivo (24, 49) , we investigated whether the severity of insult is instrumental in modulating the proliferative rates of astrocytes. AlamarBlue and thymidine incorporation assays ( fig.1A&B respectively) were used to determine the proliferative capacity of astrocytes in the presence and absence of glucose for 6 hours. As expected, different severities presented distinct proliferation patterns ( fig.1 ). No significant difference was observed between normoxic and hypoxic glucose-containing cells but anoxia stimulated increased proliferation significantly (~30%).
Surprisingly glucose withdrawal further induced proliferation. Normoxic glucose deprivation caused a 40% increase in proliferation over normoxic glucose-containing cells whereas near anoxia combined with glucose deprivation increased proliferation a further 2 fold using both techniques. In conclusion, increased severity of insult augmented proliferation of astrocytes in vitro.
Combined oxygen and glucose withdrawal induces significant cell death of astrocytes
To get a handle on how astrocytes survive oxygen and/or glucose deprivation for prolonged periods of time we measured cellular ATP levels ( fig.1C&D ). In glucose containing media ( fig.1C ) normoxic ATP levels were virtually constant for the duration of the experiment.
Hypoxia and anoxia reduced ATP levels by 50-70% within the first 6-24 hours but were subsequently maintained. Glucose deprivation ( fig.1D ) elicited a different response. A 50% decrease in normoxic ATP levels occurred within 6h glucose withdrawal before recovering to 70% at 48h and hypoxia had no additional detrimental effect on ATP levels in the absence of glucose. Anoxia combined with glucose deprivation resulted in a dramatic 70% decrease in ATP levels already at 6h that were virtually zero at 24h. Thus, although astrocytes are able to tolerate oxygen and glucose deprivation, simultaneous long-term withdrawal is ultimately 
VEGF protein is induced in the absence of HIF-1 stabilisation
VEGF, a major HIF-1 target gene, is strongly induced by hypoxia (5, 39). To determine if VEGF is upregulated in astrocytes in accordance with HIF-1 stabilisation, VEGF protein levels in conditioned media and cell lysates were measured by ELISA. Figure 2E shows increased VEGF expression in cytoplasmic fractions following oxygen deprivation. Notably, hypoxic incubation induced VEGF protein levels immediately reaching a maximum after 6h (4.5 fold increase over normoxic levels, **p=0.001) even though HIF-1 was not detected under these conditions. Interestingly, cytoplasmic VEGF induction after near anoxia was similar until 6h, but by 24h a more than 5 fold increase was observed ( fig.2E ) indicating that only prolonged anoxia (>24h) significantly induces VEGF over hypoxic conditions. Timedependent secretion of VEGF into the culture media was also monitored ( fig.2F ) but again no alterations between hypoxia and anoxia were observed until 24h. Thus during oxygen withdrawal astrocytes produce similar amounts of VEGF irrespective of the insult severity during acute insult, but chronic exposure significantly elevates VEGF production and secretion.
Immediate HIF-1 protein stabilization following an ischemic insult in vitro
An ischemic event such as stroke deprives cells of both oxygen and glucose. To mimic in vivo models of ischemia, astrocytes were placed in glucose-free media immediately prior to anoxic exposure. Glucose deprivation alone caused immediate stabilization of basal HIF-1 protein levels ( fig.3A, 0h ) and additional hypoxia further induced nuclear HIF-1 protein accumulation in a time-dependent manner. Near anoxic glucose-deprived astrocytes stabilised HIF-1 even more rapidly with a significant increase observed after just 2 hours and 3 fold induction compared to hypoxic samples after 6h ( fig. 3B ). Note that after 24 hours of anoxic incubation only residual protein levels were extracted implying major cell death at that time.
Although glucose withdrawal alone resulted in immediate basal HIF-1 stabilisation (as a result of media change), prolonged glucose deprivation did not further increase HIF-1 accumulation. Analysis of astrocytes incubated in glucose-free medium under normoxic conditions for extended periods (up to 48 hours) showed no additional increase in HIF-1 accumulation and glucose replenishment also had no effect (data not shown). Thus although glucose withdrawal stabilises low basal HIF-1 levels in astrocytes additional oxygen deprivation is required to further induce protein accumulation.
Severe insult stimulates rapid and increased secretion of VEGF from astrocytes
Although glucose and oxygen deprivation increased cytoplasmic VEGF concentrations compared to normoxic controls at all timepoints ( fig.3C ), significantly more VEGF accumulated in anoxic samples. VEGF protein levels were significantly enhanced already by 4h timepoint during hypoxia but in comparison anoxic samples already exhibited a 3-fold increase. Accumulation of secreted VEGF in media also increased in a similar time-dependent manner with 3 fold higher levels in anoxic compared to hypoxic glucose deprived cells at each time point (fig.3D ). Thus VEGF production and secretion is significantly enhanced in oxygen and glucose-deprived astrocytes.
HIF-1 only partially controls VEGF induction in astrocytes during injury
To assess the contribution of HIF-1 to VEGF signalling by astrocytes during insult we performed HIF-1 knockdown studies. Using siRNA targeted inhibition we could reliably abolish HIF-1 mRNA expression ( fig.4A) . A scrambled siRNA probe had no effect on HIF-1 stabilisation. This knockdown translated to almost complete abrogation of protein stabilisation during all insult conditions ( fig.4B ). However, despite near complete Hif-1 knockdown, only 40-50% reduction of VEGF expression in astrocytes was observed in all samples regardless of the severity of insult. A graph of cytoplasmic VEGF levels as measured by ELISA after 6h is shown ( fig.4C ). Thus this data implies that although HIF-1 signalling does play a significant role, HIF-1-independent mechanisms also contribute to regulation of astrocytic VEGF.
VEGF inhibition reduces proliferation and cell survival of astrocytes
Exogenous application of VEGF has been shown to increase proliferation of astrocytes and surrounding cells in vivo. Since astrocyte VEGF expression is enhanced during injury we assessed whether endogenous VEGF modulates astrocyte proliferation and survival in vitro.
Using the VEGF inhibitor, SU1498, we show that blockade of VEGF signalling significantly reduces thymidine incorporation and therefore proliferation of astrocytes by up to 50% already after 6h exposure ( fig.5A&B ). No differences were observed between hypoxic and anoxic cells but the effect of SU1498 seemed more pronounced in the absence of glucose ( fig.5B ) -presumably due to increased stress levels of the cells. Notably, inhibition had no affect on proliferation in the absence of insult indicating that VEGF has no endogenous mitogenic effect in the absence of injury. Blocking of VEGF also led to increased cell death compared to untreated cells after 6h exposure to different severities of insult ( fig.5C ). Overall a gradual increase in cell death was observed with increased severity of insult as previously noted. Cell death levels after treatment were stable under normoxic conditions in presence of glucose and increased only marginally in absence of glucose. However inhibitor treatment during more severe injury significantly augmented cell death by 40-50%. Thus VEGF is an important astrocyte survival factor during injury.
DISCUSSION
The ability of cells to cope with reduced oxygen levels is critical to their survival but hypoxic tolerance varies greatly amongst different cell types. During hypoxia or ischemic insult loss of astrocytes causes microvascular damage and exacerbates disturbance of brain homeostasis (48). Since astrocytes are postulated to play an important role in supporting BBB function under various pathological circumstances, we investigated astrocytic responses to different degrees of injury. In particular we focused on the temporal induction of HIF-1 and its target gene VEGF, a growth factor shown not only to be cytoprotective but also responsible for increased vascular permeability during injury (38, 51) . We show that astrocytes, in contrast to most other cell types, require severe oxygen deprivation to prevent HIF-1 degradation and can survive severe ischemic conditions for up to 6 hours. Although HIF-1 is not the sole regulator of astrocyte VEGF expression, endogenous VEGF secretion during injury is important for increased astrocyte survival and proliferation.
Astrocytes are less susceptible to injury than other brain cells such as neurons. This is due, at least in part, to compensation for a lack of oxygen by switching to glycolytic metabolism (25) that allows the constant ATP levels required to ensure cell viability during stress (15) . In most experimental injury paradigms in vitro astrocytes crucially maintained their ATP levels at or above 50%. Remarkably cell survival was only significantly compromised during severe insult, when oxygen and glucose deprivation was performed in parallel, and cells were unable to recover from a 70% drop in ATP concentrations. A strong correlation seemed to exist between astrocyte proliferation and cell death during severe insult despite reduced ATP content.
Studies by Jelluma et al (18) showed that astrocytes proliferate during sole glucose withdrawal and our data confirm this and provide good evidence that injury severity is a strong proliferative stimulus. Both hypoxia and ischemia also activate and promote proliferation of resident astrocytes in vivo (33, 50) , a process often referred to as astrogliosis or glial scarring. Suggested to be a reparative process to restore homeostasis through isolation of the damaged region, a glial scar may also detrimentally interfere with subsequent neural repair or axonal regeneration, cause release of microglial-associated inflammatory factors as well as alter cellular interactions at the BBB. Our data suggest that preventing astrocytic proliferation, especially within the first 6 hours of ischemic injury, may be beneficial to reduce scarring. (44) (35). As such increased HIF-1 stabilisation that we observe after more severe oxygen deprivation, and in combination with glucose withdrawal, is a likely prerequisite for astrocytes to increase their glycolytic capacity (25) and thus withstand further insult. In vivo, Kaur et al (20) showed that HIF-1 is stabilized in the cerebellum at inspired oxygen levels of 7% -corresponding to the O 2 concentrations inspired at an altitude of 8500m above sea level -and is therefore definitely an extremely severe hypoxic exposure. This also implies that exceptionally low concentrations of O 2 were delivered to the brain, however as they used whole tissue lysates it was unclear which cells specifically upregulated expression of the protein. Since astrocytes did not induce detectable HIF-1 during mild insult, our data suggests that early expression of HIF-1 in response to injury in vivo comes mainly from more oxygen sensitive cells such as neurons as shown in vivo by Stroka et al (42) and Chavez et al 2000 (7) . It has been proposed that abundance and hydroxylase capacity of prolyl hydroxylases may fine-tune the cellular dynamic range of oxygen sensitivity and be rate-limiting for HIF-1 degradation (41), thus defining the cellular response to insult. However existence of such a cellular mechanism is still to be clarified.
VEGF, a well-described HIF-1 target gene, is strongly induced during development but is constitutively expressed at nearly undetectable levels in adulthood under normoxic conditions (2, 5, 28) . VEGF is also upregulated during pathological processes in the brain (28, 31, 32) and in vitro (8, 14, 17, 39) . Indeed hypoxic exposure moderately increased cytoplasmic accumulation and basal release of VEGF in our astrocyte cultures in a time-dependent manner. In vivo this response seems to be advantageous since enhanced VEGF release probably protects neighbouring cells through paracrine mechanisms (8, 47) . Importantly in our model increased severity of insult progressively augmented VEGF release, with glucosefree astrocyte conditioned media containing dramatically elevated concentrations compared to glucose-containing conditioned media, in agreement with other studies of hypoglycaemic VEGF induction in glioblastoma and monocytes (37, 40) . Although moderate upregulation of VEGF probably enhances survival of surrounding cells, a rapid and massive increase in concentrations would have an overall negative effect on surrounding vasculature causing increased permeability and vascular remodelling and resulting in BBB disruption (38, 51) .
Indeed the temporal upregulation of VEGF in our model reflects the profile of BBB leakage in vivo, with VEGF induced as early as 1-3 h after focal cerebral ischemia onset and peaking at 24-48h (9, 32). Thus taken together this data implies that astrocytes have the capacity to secrete significant amounts of VEGF during ischemic injury that can induce BBB leakage.
Thus, preventing the action of high VEGF concentrations may not only attenuate significant proliferation of astrocytes but also improve BBB integrity. Surprisingly, our data advocates that insult-induced VEGF expression in astrocytes does not fully depend on HIF-1. Notably, hypoxic elevation of VEGF occurred in the absence of detectable HIF-1 stabilisation suggesting that a HIF-1-independent regulatory mechanism also exists during mild oxygen deprivation. Knockdown of HIF-1 by siRNA further supported this finding reducing VEGF expression by only 50%. Although an obvious alternative candidate is HIF-2 , during our study constitutive HIF-2 expression levels were unaffected by hypoxia (data not shown) in agreement with others (29). Thus how VEGF is hypoxically induced in the absence of HIF-1 remains intriguing and deserves further investigation. Crucially, very recent evidence by Arany et al (4) shows that the transcriptional co-activator PGC-1 powerfully regulates VEGF expression independent of HIF signalling during nutrient and oxygen insufficiency in a number of cells. Such a mechanism may also be plausible for astrocytes.Exogenous application of VEGF promotes astrocyte proliferation and can act as a paracrine cytoprotective factor in vivo (24, 26, 47) . However the possible impact of endogenous VEGF secretion on astrocyte responses to injury per se have not been well documented. Importantly, we show that endogenously produced VEGF plays an important role in astrocyte fate during injury. Blockade of VEGF signalling pathways significantly decreased proliferation but also increased astrocyte cytotoxicity. Thus endogenous VEGF secretion plays a significant autocrine role in proliferation and survival after injury via receptor-mediated effects. The finding that abrogation of autocrine VEGF signalling modulates astrocyte mitogenicity and degeneration provides an impetus for examining the role of VEGF in astroglial scarring after CNS injury. Since our data illustrate that varying levels of VEGF have differential outcome on astrocytes, fine-tuning protein concentrations could have beneficial effects on both injury progression and recovery. Although complete inhibition of VEGF, a survival factor for many cells, would probably be detrimental -indeed it has been shown that VEGF is integral to the wound repair process (21) -it seems favourable concentrations that reduce or delay astrocyte proliferation but still have cytoprotective function could be identified. Hopefully, the positive knock-on effect of this would be reduced permeability of the BBB vasculature. More studies are needed to assess the feasibility of such possibilities.
PERSPECTIVES AND SIGNIFICANCE
We show that cultured astrocytes require severe oxygen deprivation for HIF-1 induction to occur. During severe insult VEGF secretion correlates with HIF-1 induction, although evidence also suggests additional regulation via HIF-1-independent mechanisms during mild injury. Importantly, endogenous VEGF plays a significant autocrine role in promoting both survival and proliferation of astrocytes during injury. Since impairment or alteration of astrocyte function results in microvascular damage and accelerates neuronal death/hyperactivation, and VEGF has an important role in BBB leakage and CNS edema formation, such knowledge may be useful for developing selective treatment for improved brain recovery after injury. 
